Nexalin Technology Receives Nasdaq Listing Status Notification
Rhea-AI Summary
Nexalin Technology (Nasdaq: NXL) received a Nasdaq notification dated January 21, 2026 stating it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after 30 consecutive business days below the $1.00 bid threshold. The company has been granted 180 calendar days, until July 20, 2026, to regain compliance by achieving a closing bid of at least $1.00 for a minimum of 10 consecutive trading days. Shares will continue to trade uninterrupted under ticker NXL. The company said it will monitor the bid price and is considering measures to improve its financial position; it is not considering a reverse stock split at this time.
Positive
- Nasdaq granted a 180-day compliance period until July 20, 2026
- Shares will continue trading uninterrupted under ticker NXL
- Company is actively monitoring the bid price and evaluating remedies
Negative
- Company is not meeting Nasdaq minimum bid price of $1.00
- Deficiency confirmed after 30 consecutive business days below $1.00
- Must reach $1.00 closing price for 10 consecutive trading days to cure
- Failure to regain compliance by July 20, 2026 may lead to delisting
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: INBS +2.59%, NVNO +6.27%, CODX +8.73% versus AIMD -1.6% and ALUR -3.6%, suggesting stock-specific pressure around NXL’s Nasdaq notice rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Clinical trial data | Positive | +8.1% | Peer-reviewed ADHD DIFS™ trial showed improved attention and brain activity. |
| Dec 03 | Regulatory meeting | Positive | +1.6% | FDA Q-Submission meeting clarified Gen-2 SYNC Alzheimer’s pilot framework. |
| Dec 02 | Investor outreach | Positive | +5.4% | Live investor webinar announcement highlighting technology, pipeline, and market focus. |
| Nov 18 | Case report data | Positive | -1.9% | Single-patient gambling disorder case report with promising outcomes in China. |
| Nov 13 | Commercial agreement | Positive | -7.1% | Exclusive Gen-2 SYNC distribution deal in Israel after local regulatory approval. |
Recent clinically focused and strategic news often saw positive price reactions, though some commercialization and distribution updates coincided with selloffs.
Over the last few months, Nexalin released several clinically and strategically important updates. On Jan 14, 2026, ADHD DIFS™ trial data coincided with a +8.12% move. An FDA Q-Submission meeting update on Dec 3, 2025 and an investor webinar on Dec 2, 2025 both aligned with modest gains. In contrast, a gambling disorder case report on Nov 18, 2025 and an Israeli distribution deal on Nov 13, 2025 were followed by negative moves, highlighting that not all positive operational news translated into price strength.
Market Pulse Summary
This announcement highlights Nexalin’s non-compliance with Nasdaq’s US$1.00 minimum bid price and a 180-day window, until July 20, 2026, to regain compliance via at least 10 consecutive trading days at or above that level. Against a backdrop of continued operating losses and going concern language in recent filings, investors may focus on how management’s planned operational measures, clinical milestones, and capital-raising tools influence both financial position and listing status over time.
Key Terms
minimum bid price financial
reverse stock split financial
nasdaq regulatory
notification letter regulatory
continued listing regulatory
AI-generated analysis. Not financial advice.
HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a notification letter (the "Notification Letter") from the Nasdaq Stock Market LLC (the "NASDAQ") dated January 21, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ. This press release is issued pursuant to NASDAQ Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.
NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US
In accordance with the NASDAQ Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until July 20, 2026, to regain compliance with NASDAQ Listing Rule 5550(a)(2). To regain compliance, the Company's shares must have a closing bid price of at least US
The receipt of the Notification Letter has no immediate effect on the listing of the Company's shares, which will continue to trade uninterrupted on NASDAQ under the ticker "NXL". To address this issue, the Company intends to continuously monitor its bid price and is in the process of considering various measures to improve its financial position and results of operations, which the Company expects to counter the short-term adverse effects on its trading price and cure the deficiency in due time. The Company is not considering a reverse stock split at this time.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's medical devices are believed to be non-invasive and undetectable to the human body. The Nexalin products are developed to provide relief to those afflicted with mental health issues using bioelectronic medical technology. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
What Nasdaq action did Nexalin (NXL) receive on January 21, 2026?
How long does Nexalin (NXL) have to regain Nasdaq compliance?
What must Nexalin (NXL) achieve to cure the Nasdaq deficiency?
Will Nexalin (NXL) be delisted immediately after the notice?
Is Nexalin (NXL) planning a reverse stock split to regain compliance?
